STTR Phase I: Aptamer Biosensors with the Longevity and Technology Compatibility Required for Continuous Biosensing Devices Beyond Glucose

这项小型企业技术转移（STTR）第一阶段项目的更广泛影响/商业潜力是改善有可穿戴生物传感器需求的患者的临床结果。该项目将开发可穿戴式连续葡萄糖生物传感器平台，以解决一系列广泛的疾病和健康应用，例如测量与糖尿病管理相关的额外分子，改善心血管疾病的管理，以及治疗药物监测以定制剂量。除了影响美国的人类健康（特别是慢性病）外，商业市场也很重要，价值约为每年1200亿美元。此外，这些生物传感器将直接向患者提供数据，以告知他们的决定。这个小型企业技术转移（STTR）一期项目将解决连续诊断监测平台在酶传感器检测葡萄糖之外增加临床应用的局限性。与酶促葡萄糖传感器不同，电化学适体传感器可以快速适应测量体内其他分子，具有高特异性和敏感性。然而，适体传感器目前在活体动物中降解迅速（6-12小时），必须通过高侵入性切口插入。这个STTR一期项目将展示适体生物传感器在真实生物流体环境中的强大和更持久的功能。它将使用一种软件激活的方法，只插入一个电极，使最终的设备真正微创。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to improve clinical outcomes for patients with wearable biosensor needs. This project will develop wearable continuous glucose biosensor platforms to address a broad set of disease and wellness applications, such as measuring additional molecules relevant to diabetes management, improving management of cardiovascular diseases, and therapeutic drug monitoring to customize dosages. In addition to impacting human health (particularly for chronic diseases) in the United States, the commercial market is significant and valued at approximately $120 B/year. Furthermore, these biosensors will provide data directly to patients to inform their decisions. This Small Business Technology Transfer (STTR) Phase I project will address the limitations which have prevented continuous diagnostic monitoring platforms from adding clinical utility beyond sensing glucose with enzymatic sensors. Unlike enzymatic glucose sensors, electrochemical aptamer sensors are rapidly adaptable to measuring other molecules in the body with high specificity and sensitivity. However, aptamer sensors currently degrade rapidly in live animals (6-12 hours) and must be inserted through a highly-invasive incision. This STTR Phase I project will demonstrate robust and longer-lasting functioning of aptamer biosensors in a real biofluid environment. It will use a software-enabled method in which only one electrode is inserted, making the resulting device truly minimally invasive.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.